Genscript Biotech (HK:1548)
:1548
Want to see HK:1548 full AI Analyst Report?
Top Page
Genscript Biotech
(1548)
Select Model
Select Model
Rating:59Neutral
Price Target:
HK$14.00
▲(1.74% Upside)
Action:ReiteratedDate:04/16/26
The score is primarily supported by improved 2025 operating performance and a return to positive operating and free cash flow, alongside manageable leverage. This is tempered by highly volatile net income and an inconsistent cash-flow track record, while technicals are constructive but somewhat stretched and valuation is pressured by losses (negative P/E).
Positive Factors
Revenue and margin recovery
A 74% revenue rebound in 2025 combined with high gross (~57.7%) and stronger EBIT margins indicates the core services and product mix can scale profitably. Durable margins in a services-led model imply pricing power and operational leverage that support sustainable operating performance over months.
Negative Factors
Highly volatile net income
Large year-to-year swings in net income undermine earnings predictability and complicate capital allocation. Volatility suggests results are influenced by non-recurring items, tax/one-offs or timing effects, limiting confidence that operating improvements will produce stable reported profits over coming quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue and margin recovery
A 74% revenue rebound in 2025 combined with high gross (~57.7%) and stronger EBIT margins indicates the core services and product mix can scale profitably. Durable margins in a services-led model imply pricing power and operational leverage that support sustainable operating performance over months.
Read all positive factors
Genscript Biotech (1548) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$30.15B
Dividend YieldN/A
Average Volume (3M)11.61M
Price to Earnings (P/E)―
Beta (1Y)1.02
Revenue GrowthN/A
EPS GrowthN/A
CountryHK
Employees5,568
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.80
Shares Outstanding2,188,046,400
10 Day Avg. Volume8,707,016
30 Day Avg. Volume11,605,265
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.87
Price to Sales (P/S)3.60
P/FCF Ratio14.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$17.42Price Target Upside26.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.03
Revenue Forecast (FY)HK$805.93M
Genscript Biotech Business Overview & Revenue Model
Company Description
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in North America, Europe, the People's Republic of China, Japan, the other Asia Pacific regions, and i...
How the Company Makes Money
GenScript makes money primarily by selling fee-based services and related products to organizations conducting biological research and drug development. Key revenue streams include: (1) Life science research services and products: revenue from cus...
Genscript Biotech Earnings Call Summary
Earnings Call Date:Aug 17, 2025
(Q2-2025)
| Next Earnings Date:Aug 19, 2026
Earnings Call Sentiment Positive
The earnings call highlighted significant revenue growth across all segments, strong performance of Legend Biotech's CAR-T product, and a robust cash position. However, the Group faced challenges with net losses due to Legend Biotech, temporary impacts on gross margins, and capacity issues in ProBio. Despite these challenges, the positive achievements and growth outweigh the difficulties.Positive Updates
Record Revenue Growth
The Group's revenue increased by 81.9% year-over-year to approximately USD 519 million. All three segments achieved growth, with GenScript Life Science growing by 11.3%, ProBio by 511%, and Bestzyme by 8.4%.
Negative Updates
Net Loss Due to Legend Biotech
The Group's net loss was approximately USD 24.5 million, significantly impacted by Legend Biotech's current period loss and the amortization impact of a USD 3.2 billion variation increase when it was deconsolidated in 2024.
Read all updates
Q2-2025 Updates
Positive
Negative
Record Revenue Growth
The Group's revenue increased by 81.9% year-over-year to approximately USD 519 million. All three segments achieved growth, with GenScript Life Science growing by 11.3%, ProBio by 511%, and Bestzyme by 8.4%.
Read all positive updates
Company Guidance
During the 2025 interim results conference call, GenScript provided detailed guidance on their financial and operational performance for the first half of the year and projections for the second half. The company reported an impressive 82% year-over-year revenue growth, with the adjusted profit from continuing operations significantly increasing to approximately USD 180 million. Key highlights included the GenScript Life Science business achieving an 11.3% revenue increase to USD 248 million, and ProBio exhibiting a robust 511% growth to USD 247 million. Bestzyme also experienced a revenue rise of 8.4% to USD 28.3 million. Legend Biotech's CAR-T product, CARVYKTI, treated over 7,500 patients and saw a 136% increase in net trade sales to USD 439 million. GenScript forecasts continued growth, with GenScript Life Science's full-year revenue expected to increase by 13% to 15% and anticipates ProBio to recognize additional milestone payments in the second half. The company maintains a strong cash position of USD 970 million, supporting global expansion and R&D initiatives. Additionally, GenScript remains committed to advancing ESG initiatives, earning a silver medal from EcoVadis and an AA rating from MSCI ESG, reflecting their dedication to sustainability and governance.Genscript Biotech Financial Statement Overview
Summary
Income Statement
54
Neutral
Balance Sheet
72
Positive
Cash Flow
60
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 960.95M | 594.49M | 839.53M | 625.70M | 490.10M |
| Gross Profit | 554.02M | 272.13M | 270.63M | 304.08M | 282.52M |
| EBITDA | 329.77M | 70.43M | -249.42M | -389.04M | -477.27M |
| Net Income | -533.62M | 2.96B | -95.48M | -226.85M | -358.71M |
Balance Sheet | |||||
| Total Assets | 4.85B | 5.28B | 3.39B | 2.55B | 2.23B |
| Cash, Cash Equivalents and Short-Term Investments | 843.01M | 621.18M | 1.93B | 1.46B | 1.41B |
| Total Debt | 523.15M | 723.74M | 416.99M | 349.80M | 156.45M |
| Total Liabilities | 876.30M | 954.91M | 1.34B | 1.18B | 846.17M |
| Stockholders Equity | 3.96B | 4.32B | 1.39B | 1.01B | 1.05B |
Cash Flow | |||||
| Free Cash Flow | 241.69M | -72.27M | -444.62M | -336.40M | -269.83M |
| Operating Cash Flow | 325.52M | 75.65M | -286.91M | -120.29M | -136.79M |
| Investing Cash Flow | -171.95M | -1.46B | -357.73M | -443.30M | -212.55M |
| Financing Cash Flow | -144.89M | 66.52M | 1.07B | 419.32M | 902.14M |
Genscript Biotech Technical Analysis
Positive
13.76
Price Trends
11.91
Positive
12.93
Positive
14.82
Negative
Market Momentum
0.49
Negative
71.03
Negative
92.21
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1548, the sentiment is Positive. The current price of 13.76 is above the 20-day moving average (MA) of 11.95, above the 50-day MA of 11.91, and below the 200-day MA of 14.82, indicating a neutral trend. The MACD of 0.49 indicates Negative momentum. The RSI at 71.03 is Negative, neither overbought nor oversold. The STOCH value of 92.21 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1548.
Genscript Biotech Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | HK$47.27B | 20.04 | 6.54% | 1.57% | 15.01% | 18.33% | |
63 Neutral | HK$138.70B | 11.12 | 10.55% | ― | 16.79% | 49.13% | |
63 Neutral | HK$55.97B | 18.63 | 11.48% | 1.04% | 14.96% | -7.11% | |
59 Neutral | HK$30.15B | -6.48 | -12.75% | ― | ― | ― | |
53 Neutral | HK$3.64B | 15.94 | 5.53% | ― | -12.90% | 33.65% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | HK$2.02B | 38.28 | 1.98% | ― | 0.61% | 770.00% |
* Healthcare Sector Average
HK:1548
Genscript Biotech
13.61
2.67
24.41%
HK:2269
Wuxi Biologics (Cayman)
33.28
10.18
44.07%
HK:3759
Pharmaron Beijing Co., Ltd. Class H
20.60
7.10
52.58%
HK:1521
Frontage Holdings Corp.
1.01
-0.16
-13.68%
HK:1873
Viva Biotech Holdings
1.70
0.19
12.58%
HK:6821
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
105.00
49.95
90.74%
Genscript Biotech Corporate Events
Genscript Highlights Strong Q1 2026 CARVYKTI Sales via Legend Biotech
Apr 14, 2026
Genscript Biotech reported that its associate Legend Biotech generated approximately US$597 million in net trade sales from the CARVYKTI® therapy in the quarter ended 31 March 2026, based on figures provided by collaboration partner Janssen B...
Genscript Biotech Sets 2026 AGM to Approve Accounts, Board Mandates and Share Issuance Authority
Apr 13, 2026
Genscript Biotech has called its 2026 annual general meeting for 5 June 2026 in Jiangning District, where shareholders will review and adopt the audited consolidated financial statements for the year ended 31 December 2025. They will also consider...
Genscript Biotech Proposes Governance Overhaul to Align With Updated Listing Rules
Apr 10, 2026
Genscript Biotech Corporation plans to revise its existing memorandum and articles of association to adopt a fifth amended and restated version, aiming to align its constitutional documents with recent changes to Hong Kong Listing Rules and applic...
Genscript Biotech Names New Company Secretary and Authorised Representative
Mar 15, 2026
Genscript Biotech Corporation has announced a change in its corporate governance personnel, with company secretary and authorised representative Ms. Wong Wai Ling resigning effective 15 March 2026. The board noted that Ms. Wong has no disagreement...
Genscript Biotech’s Core Earnings Surge but Legend Impairment Drives 2025 Net Loss
Mar 15, 2026
Genscript Biotech reported a sharp acceleration in operating performance for 2025, with revenue from continuing operations surging 61.4% to US$959.5 million, driven largely by a substantial rise in license income and solid growth across other busi...
Genscript flags 2025 loss on Legend impairment despite surge in licensing profit
Mar 10, 2026
Genscript Biotech expects adjusted net profit from continuing operations for 2025 to surge to between US$207.3 million and US$241.9 million from US$59.8 million a year earlier, driven largely by a sharp rise in license revenue, notably sublicense ...
Genscript Flags Legend Biotech’s 2025 Results, Cautions Investors on Risk
Mar 10, 2026
Genscript Biotech has announced that its associate, Legend Biotech Corporation, has filed its fourth-quarter and full-year 2025 financial results and recent business highlights with the U.S. Securities and Exchange Commission via a Form 6-K. The c...
Genscript Biotech Sets March Board Meeting to Approve 2025 Annual Results
Mar 4, 2026
Genscript Biotech Corporation has scheduled a board meeting for 15 March 2026 to review and approve its annual results for the year ended 31 December 2025. The board will also decide on the publication of these results and consider whether to decl...
Genscript Chairman Joins Board of Nasdaq-Listed Associate Legend Biotech
Jan 23, 2026
Genscript Biotech has announced that its chairman and executive director, Jiange (Robin) Meng, has been appointed to the board of its associate company Legend Biotech Corporation, effective 20 January 2026, replacing outgoing director Li Zhu with ...
Genscript Highlights Strong Q4 2025 CARVYKTI® Sales Reported by Legend Biotech
Jan 21, 2026
Genscript Biotech has disclosed that its associate Legend Biotech reported approximately US$555 million in net trade sales of the multiple myeloma cell therapy CARVYKTI® for the quarter ended 31 December 2025, based on figures provided by com...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.